Mantle Cell Lymphoma | Specialty

Dr. Jain on Future Research Efforts Examining Venetoclax Resistance Patterns in MCL

June 24th 2020

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Future Directions in Mantle Cell Lymphoma

June 24th 2020

ASCO 2020: ZUMA-2 Update

June 24th 2020

Bruton Tyrosine Kinase Inhibitors

June 24th 2020

A Look at ZUMA-2 Trial

June 24th 2020

An Introduction to Mantle Cell Lymphoma & KTE-X19

June 24th 2020

Dr. Lee on B-Cell Receptor Targeting in Relapsed/Refractory MCL

June 23rd 2020

Hun Ju Lee, MD, discusses B-cell receptor targeting in relapsed/refractory mantle cell lymphoma.

Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen

June 23rd 2020

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

June 22nd 2020

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCL

June 20th 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Karmali on Treating Older Patients With MCL in the Rituximab Era

June 16th 2020

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.

Cirmtuzumab Plus Ibrutinib Shows Activity and Tolerability in MCL and CLL

June 16th 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maintenance Rituximab Improves Survival in Older Patients With MCL, But More Work Needed

June 16th 2020

Reem Karmali, MD, discusses survival outcomes in older patients with MCL with maintenance rituximab and highlights other ongoing MCL research efforts to optimize maintenance strategies in this patient population.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Dr. Ruan on Stratifying Risk in MCL

June 9th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

June 6th 2020

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL

June 3rd 2020

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

June 3rd 2020

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.